Lymphoma
Researchers from Harvard University, Medical Department detail new studies and findings in the area of lymphoma
Published in Cancer Weekly, June 2nd, 2009
"We studied the response and adverse effects of intravenous high-dose MTX in patients who were 70 or more years of age at the time of diagnosis. We identified 31 patients at our institution diagnosed with PCNSL at age >= 70 years (median, 74 years) who were treated with high-dose MTX (3.5-8 g/m(2)) as initial therapy from 1992 through 2006. The best response to MTX was...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2009-06-02)
More Articles from Cancer Weekly
- Allergies
Study data from National Institute of Allergy and Infectious Diseases update knowledge of allergies - Allos Therapeutics, Inc.
Allos Therapeutics Announces Updated Data from Pivotol Phase 2 PROPEL Study of Pralatrexate to be Presented at ASCO 2009 - Cancer Gene Therapy
New cancer gene therapy findings from University of Saskatchewan described - Cancer Gene Therapy
Reports outline cancer gene therapy study findings from University of Navarra - Cancer Gene Therapy
Research from Central South University has provided new information about cancer gene therapy - Cancer Gene Therapy
Research reports from University Hospital provide new insights into cancer gene therapy - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
